issues are needed in anorexics. Nonetheless, our findings indicate a close relationship between serum HMGB1, refeeding progress and RR that warrants future investigations as a potential therapeutic target in AN. 
Is ASMT a susceptibility gene for autism spectrum disorders? A replication study in European populations may play a role in autism spectrum disorders (ASDs). Children with autism have been observed to show pineal hypofunction, with low melatonin production and co-occurrence of sleep disturbances and altered circadian rhythms. 1 Acetylserotonin O-methyltransferase (ASMT) is the enzyme involved in the last step of melatonin synthesis, 2 and is encoded by the ASMT gene in the PAR1 region of the sex chromosomes. Recently, Melke et al.
3 performed mutation screening of the ASMT gene in 250 individuals with ASDs and identified several rare variants with a likely functional role; these included a splice site mutation (IVS5 þ 2T > C) present in two ASD families but not in 426 controls, which was associated with low ASMT activity and melatonin concentration. Moreover, significant association was reported for two single nucleotide polymorphisms (SNPs) located in one of the two alternative promoters of the gene (rs4446909 and rs5989681). For both SNPs, the major allele was more frequent in ASD cases compared to controls, and was associated with low ASMT transcript levels in lymphoblastoid cell lines. Taken together, these data suggested that ASMT gene variants might be involved in susceptibility to ASDs.
To investigate further these findings, we screened the ASMT gene in three independent collections of ASD families and controls: a The assessment methods and inclusion criteria for the three family collections have been described previously. [4] [5] [6] Mutation screening has been performed by sequencing all nine exons and promoter regions of ASMT gene in 47 Italian affected individuals, in 20 probands from IMGSAC multiplex families, and in the entire Finnish ASD cohort, for a total of 194 individuals (primer sequences are available on request). Fragments containing exons 5 and 9 were subsequently screened in all remaining Italian and IMGSAC probands and in controls, as these exons contained rare DNA variants likely to have a damaging effect on protein function.
Mutation screening results are summarized in Table 1 . Several rare mutations were identified, including the splice site mutation IVS5 þ 2T > C and the L326F substitution reported previously by Melke et al. 3 In our study, the splice site mutation was not only found in three families but also in one control individual. Moreover, this mutation does not segregate with the ASD phenotype in one Italian family (it is also transmitted from the mother to an unaffected sister) and in one IMGSAC sib-pair family (it is transmitted from the father to only one of the two affected sibs), suggesting that it does not strongly contribute to the ASD phenotype. Interestingly, a new R319X stop mutation has been found in a single autism proband of Italian origin and is absent from the entire control sample. This mutation truncates the methyl-transferase domain of the protein, thus probably causing loss of ASMT activity.
In order to replicate the association results obtained by Melke et al., 3 we also carried out a case-control study using the four SNPs in ASMT promoter B (Table  2 ). Genotypes were determined by sequencing. Single marker and haplotype association was carried out using Haploview. 7 No significant association was seen for any of the SNPs or haplotypes in each independent family and control sample, as well as in the combined sample.
In conclusion, although the finding of a stop mutation is noteworthy, our data does not support a correlation between ASMT gene variants and increased susceptibility to ASDs. The damaging IVS5 þ 2T > C variant did not segregate with autism within families, and promoter polymorphisms known to be associated with low transcript levels showed no allele frequency differences in our large collection of cases and controls.
A possible involvement of ASMT gene variants in susceptibility to other neuropsychiatric disorders cannot be excluded. The four affected individuals The trace amine-associated receptor genes (TAARs) have been considered as important candidates for both schizophrenia (SZ) and bipolar disorder (BD) based on mapping, 1,2 expression 3 and association of TAAR6 (a.k.a. TRAR4) with BD and SZ. 4, 5 Clinical studies have demonstrated elevated urinary levels of one of the trace amines (b-phenylethylamine) in SZ and BD patients. 6, 7 To replicate the reported association and further explore roles of other trace amine receptors in BD susceptibility, we performed a family-based association analysis of all the known nine TAAR genes in 1310 samples, which consisted of 989 samples from the NIMH (National Institute of Mental Health) Genetics Initiative for Bipolar Disorder Waves 1-4 series (including waves 1-2: 23 trios and 83 quads; waves 3-4: 22 trios and 112 quads); 83 samples from the Clinical Neurogenetics (CNG) series (including 6 trios and 8 quads); and 238 samples from the ChicagoHopkins-Intramural Project (CHIP) series (including 14 trios and 49 quads). The NIMH wave 3 samples showed linkage with 6q23 in previous genome scan study. 8 All affected children met DSM-IV criteria for bipolar or schizoaffective bipolar type based on the A total of 10 000 permutations of association results were performed using Haploview 4.0 to obtain a measure of significance corrected for multiple testing bias.
